Atrial Fibrillation: Contemporary Assessment and Management

Conceptual illustration; the displayed waveform is not a diagnostic ECG.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice. Its clinical significance extends beyond an irregular rhythm: AF is associated with thromboembolism, stroke, heart failure, impaired quality of life, recurrent hospitalization, and increased cardiovascular morbidity.

Contemporary management has evolved from simply choosing between “rate control” and “rhythm control” toward an integrated strategy that addresses the underlying cardiovascular substrate, thromboembolic risk, symptoms, rhythm burden, comorbidities, and the patient's preferences.

The 2024 European Society of Cardiology guidelines organize this approach through the AF-CARE pathway: Comorbidity and risk-factor management, Avoidance of stroke and thromboembolism, Reduction of symptoms through rate and rhythm control, and Evaluation with dynamic reassessment.

When to Seek Emergency Help

Call 999 in Qatar for possible stroke symptoms, including sudden facial drooping, arm weakness or speech difficulty—even if they resolve. Severe chest pain, marked breathlessness or collapse also require emergency assessment. [6]

Do not wait for a routine appointment or a response through this website.

Diagnosis and Initial Assessment

The diagnosis of clinical AF should be confirmed by electrocardiographic documentation. Once AF is established, evaluation should go beyond confirming the arrhythmia.

Clinical assessment should define the AF pattern, symptom burden, ventricular response, potential triggers, thromboembolic risk, bleeding modifiers, and associated cardiovascular disease. A 12-lead ECG, transthoracic echocardiography and appropriate laboratory evaluation are central to the initial work-up.

Echocardiography provides important information regarding left ventricular function, left atrial remodeling, valvular disease, pulmonary pressures and other structural abnormalities that may influence prognosis and treatment selection.

Evaluation should also actively identify hypertension, heart failure, obesity, diabetes, sleep-disordered breathing, alcohol exposure, physical inactivity and other modifiable factors because these conditions contribute to AF progression and recurrence.

An automated smartwatch notification or an irregular pulse alone does not establish clinical AF. ECG evidence requires clinician review. Device-detected atrial high-rate episodes and subclinical AF require a separate assessment of episode duration, stroke risk and bleeding risk; they should not automatically be managed as established clinical AF. [1,2]

AF-CARE: Treat the Cardiovascular Substrate

Risk-factor and comorbidity management is no longer an adjunct to AF therapy; it is a core component of treatment.

Optimal blood-pressure control, appropriate heart-failure therapy, weight reduction in overweight or obese patients, regular physical activity, diabetes management, evaluation for obstructive sleep apnea and reduction of excessive alcohol intake can reduce AF burden and improve the effectiveness of rhythm-control interventions.

The 2024 ESC guideline specifically emphasizes comprehensive risk-factor management and recommends substantial weight reduction in appropriate overweight or obese patients, regular aerobic activity and marked limitation of alcohol intake as part of an integrated AF strategy.

Stroke Prevention and Anticoagulation

Prevention of thromboembolism is one of the most consequential decisions in AF management.

The 2024 ESC guideline uses the CHA₂DS₂-VA framework as one option for risk assessment, removing sex category from the score used to guide anticoagulation. Oral anticoagulation should be considered when CHA₂DS₂-VA is 1 and is recommended when the score is 2 or greater, provided there is no contraindication. The 2023 ACC/AHA/ACCP/HRS guideline similarly recommends using a validated thromboembolic-risk assessment and basing treatment on the patient's estimated stroke risk rather than the AF pattern itself.

The ESC CHA₂DS₂-VA and ACC/AHA CHA₂DS₂-VASc frameworks are distinct; their thresholds should not be interchanged. [1,2]

For most eligible patients, direct oral anticoagulants are preferred over vitamin K antagonists. Important exceptions include patients with mechanical prosthetic valves and moderate-to-severe mitral stenosis, where vitamin K antagonist therapy remains appropriate. [1,2]

Antiplatelet therapy should not be used as a substitute for anticoagulation when anticoagulation is indicated. Likewise, inappropriate dose reduction of a DOAC should be avoided unless the patient meets the drug-specific criteria for dose reduction.

Bleeding-risk assessment should be used primarily to identify and correct modifiable bleeding factors and to determine the intensity of follow-up—not simply to deny anticoagulation to a patient who otherwise derives substantial stroke-prevention benefit.

In AF with hypertrophic cardiomyopathy or cardiac amyloidosis, anticoagulation is recommended irrespective of the CHA₂DS₂-VA score. [1]

Rate Control

Rate control remains an appropriate strategy for many patients, either as primary therapy or together with rhythm control.

Beta-blockers and digoxin remain individualized options according to clinical context. Diltiazem or verapamil may be used when LVEF is >40%, taking account of blood pressure and clinical stability. They should be avoided in significant LV systolic dysfunction. The choice should account for left ventricular function, blood pressure, activity level, associated disease and symptoms. [1,2]

The objective is not simply to achieve a numerical heart-rate target. Rate control should improve symptoms, avoid tachycardia-mediated ventricular dysfunction and prevent excessive bradycardia. A relatively lenient approach may be sufficient in clinically stable patients, while persistent symptoms or suspected tachycardia-induced cardiomyopathy may justify tighter control and additional monitoring.

Rhythm Control: Earlier and More Individualized

The role of rhythm control has expanded substantially.

Contemporary guidelines encourage consideration of rhythm control in suitable patients rather than reserving it exclusively for those who remain severely symptomatic despite rate control. Rhythm-control strategies include electrical or pharmacological cardioversion, antiarrhythmic medication and catheter ablation.

The 2024 ESC guideline supports consideration of a rhythm-control strategy within the first 12 months after diagnosis in selected patients with cardiovascular risk, reflecting evidence that earlier rhythm management may reduce cardiovascular events in appropriately selected populations.

The decision should incorporate symptoms, AF duration and burden, atrial remodeling, ventricular function, comorbidities, likelihood of maintaining sinus rhythm, drug safety, procedural considerations and patient preference.

Antiarrhythmic Drug Safety

Drug selection depends on structural heart disease, ventricular function, kidney function, QT interval and interactions.

Flecainide and propafenone should not be used in patients with previous myocardial infarction or significant structural heart disease. Amiodarone requires surveillance for extracardiac toxicity; sotalol and dofetilide require careful QT and renal assessment.

A ‘pill-in-the-pocket’ strategy is appropriate only for selected patients after supervised evaluation and an explicit prescription plan. It is not a general self-treatment strategy. [1,2]

Cardioversion

Electrical cardioversion remains one of the most effective methods for rapid restoration of sinus rhythm.

Safety around cardioversion requires careful attention to anticoagulation and the estimated duration of AF. For AF of sufficient duration or uncertain onset, elective cardioversion generally requires an appropriate period of therapeutic anticoagulation beforehand or an imaging-guided strategy to exclude left atrial thrombus.

The 2024 ESC guidance emphasizes delaying cardioversion and providing at least three weeks of anticoagulation when AF duration exceeds 24 hours unless an appropriate alternative strategy is used. Anticoagulation after cardioversion is continued according to procedural recommendations and the patient's long-term thromboembolic risk.

Importantly, successful restoration of sinus rhythm does not by itself eliminate the need for long-term anticoagulation in a patient whose underlying stroke risk remains elevated.

Haemodynamic instability attributable to AF requires urgent electrical cardioversion.

After cardioversion, anticoagulation is generally continued for at least four weeks. ESC 2024 allows a narrow exception when there are no thromboembolic risk factors and sinus rhythm is restored within 24 hours of definite AF onset. Long-term treatment depends on stroke risk, not apparent rhythm success. [1,2]

A short duration of symptoms does not reliably establish recent onset of the arrhythmia.

Catheter Ablation

Catheter ablation has moved considerably earlier in the AF treatment pathway.

Pulmonary vein isolation remains the foundation of AF ablation. In symptomatic paroxysmal AF, catheter ablation can be considered as a first-line rhythm-control strategy in appropriately selected patients. It is also well established when antiarrhythmic therapy is ineffective, poorly tolerated or undesirable.

Evidence from randomized studies has shown that first-line catheter ablation can reduce recurrent atrial arrhythmia and may slow progression from paroxysmal toward more persistent forms of AF compared with antiarrhythmic-drug therapy.

Randomized evidence on AF progression after cryoablation: [3].

In patients with heart failure, particularly when AF contributes to ventricular dysfunction or symptoms, rhythm control and catheter ablation may provide important clinical benefit in appropriately selected individuals.

The goal is not simply procedural elimination of AF episodes, but improvement in symptoms, functional status, AF burden and, in selected populations, cardiovascular outcomes.

Anticoagulation After Ablation: Guidelines and New Trial Evidence

ESC 2024 recommends anticoagulation for at least two months after AF ablation; ACC/AHA/ACCP/HRS 2023 recommends at least three months. Subsequent treatment is guided by thromboembolic risk rather than procedural success alone. [1,2]

ALONE-AF and OCEAN provide newer randomized evidence, but they asked different questions in selected patients without documented recurrence after apparently successful ablation.

ALONE-AF compared stopping versus continuing oral anticoagulation in 840 patients. At two years, the composite of stroke, systemic embolism and major bleeding was lower with discontinuation, principally because of fewer major bleeding events. The study does not establish universal safety of withdrawal, particularly in very-high-risk patients. [4]

OCEAN compared rivaroxaban with aspirin in 1,284 patients at least one year after successful ablation. Rivaroxaban did not significantly reduce the primary composite of stroke, systemic embolism or new covert embolic stroke. Low event rates and uncertainty around the estimates matter: failure to demonstrate superiority does not establish equivalence. The trial does not make aspirin a routine substitute for indicated anticoagulation in clinical AF. [5]

These findings should inform specialist shared decision-making, with attention to baseline risk, monitoring and recurrence. They are trial evidence, not a universal instruction to stop anticoagulation. Patients should not stop or replace prescribed anticoagulants without their treating clinician.

Left Atrial Appendage Occlusion

Left atrial appendage occlusion may be considered in selected patients in whom long-term oral anticoagulation is contraindicated or problematic and stroke prevention remains necessary.

It should not be viewed simply as a routine alternative to anticoagulation for every patient with AF. Appropriate patient selection, procedural expertise and individualized assessment of thromboembolic and bleeding risks are essential.

Dynamic Reassessment

AF is not a static condition.

A patient's symptoms, rhythm burden, ventricular function, renal function, bleeding risk, age, comorbidities and thromboembolic profile can all change over time. Consequently, treatment decisions made at diagnosis should not be regarded as permanent.

Periodic reassessment is a central component of the AF-CARE strategy and allows anticoagulation, rate control, rhythm control and risk-factor management to evolve with the patient.

A Contemporary Perspective

Modern AF management is increasingly proactive and individualized.

The most effective strategy is rarely a single intervention. Optimal care integrates cardiovascular risk-factor modification, stroke prevention, thoughtful rate or rhythm control, appropriate use of ablation and repeated reassessment.

The objective is not merely to treat an abnormal ECG. It is to reduce stroke and cardiovascular complications, improve symptoms and functional capacity, prevent disease progression where possible, and align treatment with the individual patient's clinical profile and preferences.